While KRAS MT status is clearly associated with lack of response to the anti-EGFR antibody cetuximab in colorectal cancer, [23] in lung adenocarcinoma KRAS MT status does not appear to predict response to this agent [24]. This evidence concerns the gene KRAS and colorectal cancer.